title: Compliance to recommendations for the management of curative treatment of Plasmodium vivax/ovale infections.
abstract: OBJECTIVE
  We assessed the compliance to recommendations for the routine management of Plasmodium vivax/ovale malaria, and analyzed the impact of discrepancies on the quality of care.
  
  
  METHODS
  We reviewed the cases of P. ovale and P. vivax malaria treated at the Besançon University Hospital, France (2008-2013).
  
  
  RESULTS
  Chloroquine was prescribed in 44% of the 18 cases (4 due to P. ovale, 14 to P. vivax). Radical cure with primaquine was prescribed after the first bout of malaria for 6 patients. The primaquine dose prescribed was inferior to the recommended one for 4 patients. The mean delay between schizonticide treatment and primaquine cure was 43 days.
  
  
  CONCLUSIONS
  The delay before access to primaquine radical cure was the only parameter, likely to alter treatment effectiveness, but also difficult to shorten. Future national guidelines should take into account that not all patients have access to primaquine treatment immediately after schizonticide treatment.
authors.affiliation: Service des maladies infectieuses et tropicales, CHRU Jean-Minjoz, 3, boulevard Fleming, 25030 Besançon, France. Electronic address: jffaucher@chu-besancon.fr.
authors.forename: J-F
authors.initials: JF
authors.lastname: Faucher
authors.affiliation: Laboratoire de parasitologie-mycologie, CHRU Jean-Minjoz, 25030 Besançon, France.
authors.forename: A-P
authors.initials: AP
authors.lastname: Bellanger
authors.affiliation: Service des maladies infectieuses et tropicales, CHRU Jean-Minjoz, 3, boulevard Fleming, 25030 Besançon, France; Département des maladies infectieuses, CHU n(o) 1 université médicale du Xinjiang, 830054 Urumqi, République populaire de Chine.
authors.forename: N
authors.initials: N
authors.lastname: Shaniya
authors.affiliation: Service des maladies infectieuses et tropicales, CHRU Jean-Minjoz, 3, boulevard Fleming, 25030 Besançon, France.
authors.forename: L
authors.initials: L
authors.lastname: Hustache-Mathieu
authors.affiliation: Service des maladies infectieuses et tropicales, CHRU Jean-Minjoz, 3, boulevard Fleming, 25030 Besançon, France.
authors.forename: B
authors.initials: B
authors.lastname: Hoen
authors.affiliation: Service des maladies infectieuses et tropicales, CHRU Jean-Minjoz, 3, boulevard Fleming, 25030 Besançon, France.
authors.forename: C
authors.initials: C
authors.lastname: Chirouze
mesh_terms: D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D002648:Child; D002738:Chloroquine / Q000627:therapeutic use*; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D016780:Malaria, Vivax / Q000188:drug therapy; D008875:Middle Aged; D041122:Plasmodium ovale; D011319:Primaquine / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000962:Antimalarials; D002738:Chloroquine; D011319:Primaquine
keywords: Guidelines; Plasmodium vivax; Primaquine; Recommandations de pratiques cliniques